Going After Amgen's Games

Journalists are once again discovering Amgen, the bad boy of biotech. Chris Rowland of the Boston Globe today reminds his readers that the government could save a half billion dollars a year by requiring dialysis patients to take Amgen's best-selling drug Epogen via injection rather than through intravenous drip.

Last week, Amgen signed a special deal with one of the largest dialysis chains to effectively freeze out a comparable drug produced by Roche. Will the Federal Trade Commission take notice? Maybe after November 7.